Published trials using checkpoint inhibitors in lymphoma
| Checkpoint . | Disease . | Patients . | IAEs (N) . | CR or PR . | Biomarker . | References . |
|---|---|---|---|---|---|---|
| Ipilimumab | HL and NHLs (post allo-HSCT) | 17 | Thyroid (3) | 2 CR, 1 PR | ↑CD4+DR+cells | Bashey et al, 20098 |
| Lung (2) | ||||||
| NHLs | 18 | GI (5) | 1 CR, 1 PR | ↑T-cell response to recall antigens | Ansell et al, 200940 | |
| Marrow (1) | ||||||
| Pidilizumab | HL and NHLs | 8 | Fatigue (1) | 1 CR | ↑CD4+ cells | Berger et al, 200810 |
| DLBCL (post auto-HSCT, adjuvant) | 62 (35 active) | Marrow (11) | 12 CR, 6 PR | ↑PD-L1E+ T cells | Armand et al, 201341 | |
| (ORR, 51%) | ||||||
| Pidilizumab + rituximab | Follicular | 29 | None | 15 CR, 4 PR | ↑PD-L1+ T cells, 41-gene signature | Westin et al, 201411 |
| Nivolumab | HL | 23 | Marrow (1) | 6 CR, 14 PR | ↑PD-L1/L2 and pSTAT3 on tumor | Ansell et al, 201512 |
| Pancreas (1) | ||||||
| Pembrolizumab | HL (brentuximab failure) | 31 | Thyroid | 5 CR, 15 PR | ↑PD-L1 on tumor | Armand et al, 201513 |
| Lung | ↑CD4+, CD8+ | |||||
| GI (total 5) | 10-gene panel | |||||
| Nivolumab | NHLs | 54 | Lung (7%) | 2 CR, 10 PR | Pending | Lesokhin et al, 20145 |
| Skin (3%) | (ORR, 28%) | |||||
| GI (3%) |
| Checkpoint . | Disease . | Patients . | IAEs (N) . | CR or PR . | Biomarker . | References . |
|---|---|---|---|---|---|---|
| Ipilimumab | HL and NHLs (post allo-HSCT) | 17 | Thyroid (3) | 2 CR, 1 PR | ↑CD4+DR+cells | Bashey et al, 20098 |
| Lung (2) | ||||||
| NHLs | 18 | GI (5) | 1 CR, 1 PR | ↑T-cell response to recall antigens | Ansell et al, 200940 | |
| Marrow (1) | ||||||
| Pidilizumab | HL and NHLs | 8 | Fatigue (1) | 1 CR | ↑CD4+ cells | Berger et al, 200810 |
| DLBCL (post auto-HSCT, adjuvant) | 62 (35 active) | Marrow (11) | 12 CR, 6 PR | ↑PD-L1E+ T cells | Armand et al, 201341 | |
| (ORR, 51%) | ||||||
| Pidilizumab + rituximab | Follicular | 29 | None | 15 CR, 4 PR | ↑PD-L1+ T cells, 41-gene signature | Westin et al, 201411 |
| Nivolumab | HL | 23 | Marrow (1) | 6 CR, 14 PR | ↑PD-L1/L2 and pSTAT3 on tumor | Ansell et al, 201512 |
| Pancreas (1) | ||||||
| Pembrolizumab | HL (brentuximab failure) | 31 | Thyroid | 5 CR, 15 PR | ↑PD-L1 on tumor | Armand et al, 201513 |
| Lung | ↑CD4+, CD8+ | |||||
| GI (total 5) | 10-gene panel | |||||
| Nivolumab | NHLs | 54 | Lung (7%) | 2 CR, 10 PR | Pending | Lesokhin et al, 20145 |
| Skin (3%) | (ORR, 28%) | |||||
| GI (3%) |
Presented at the 57th annual meeting of the American Society of Hematology, Orlando, FL, 5-8 December, 2015.13
allo or auto-HSCT, allogeneic or autologous hematopoietic stem cell transplant; CR, complete remission; DLBCL, diffuse large B-cell lymphoma; GI, gastrointestinal toxicity; HL, Hodgkin lymphoma; IAEs, grade 3 or higher immune-related adverse events; N, number of patients affected; MM, multiple myeloma; NHLs, non-Hodgkin lymphomas; ORR, overall response rate; PR, partial remission.